Lead Time Reduction Case study:BEAB etikett & system AB

In today’s competitive business world, companies require small lead times, low costs andhigh customer service levels to survive. Because of this, companies have become morecustomer focused . The result is that companies have been putting in significant effort toreduce their lead times.The purpose of this master thesis was to reduce lead time at BEAB etikett & system AB(BEAB) by focusing both on ordering and production times. In order to achieve this allprocesses from receiving an order to shipment of the order are mapped in a current statemap. Some changes based on the Toyota Production System (TPS) were implemented.The results were then mapped in a future state map.BEAB has more than 30 years experience of producing labels in different sizes andshapes. The products’ range varies from hanger labels on clothing to self adhesive labelsfor pallets. Due to globalization and stiff competition, the 8 days lead time at BEAB hasto be reduced so that they could maintain their customers, and even increase theircustomer base.It was found that the most appropriate mapping method for lead time reduction wasValue Stream Mapping (VSM). From the results achieved by VSM it was obvious thatthe press machines were bottlenecks. In order to increase their capacity, their change overtime should be reduced. Another observation derived from the VSM, was that a neworder passing through the ordering department is an unnecessary step. Some otherrecommended changes based on applying TPS are:• Reduction of work in process inventory (WIP)• Reduction of waiting time between press and converter• Stop the process to build in quality (this sounds awkward)• Collect more information• Implementation of the 5S methodologyBy implementing these changes, the future state map was created and the total lead timewas reduced from 8 days to 6 days. The production lead time reduced from 4.35 days to 4days.Uppsatsnivå:

Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019Research in context

Summary: Background: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. Methods: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. Findings: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. Interpretation: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. Funding: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38)